03613 TONGRENTANGCM
- 9.500
- -0.100-1.04%
TONGRENTANGCM News
同仁堂國藥：2023年年報
Gelonghui Fund Daily Report | 10 billion fund manager's big move!
Focus on the latest fund information
Tong Ren Tang Sinopharm (03613): Chen Fei appointed as acting CEO
Tong Ren Tang Sinopharm (03613) announced that Yu Jin has resigned as the company's executive director and CEO due to personal matters...
Damo: Maintaining Tong Ren Tang Sinopharm's (03613) “Gain” Rating and Lowering the Target Price to HK$15
According to the optimistic hypothesis, Tongrentang Sinopharm (03613) sales growth is 20% or more per year.
Tong Ren Tang Sinopharm Announces 2023 Annual Results Profit attributable to shareholders of HK$540 million, a decrease of 16.3% year-on-year
Tong Ren Tang Sinopharm (03613) announced its results for the year ended December 31, 2023. The group achieved revenue of HK$1,525 million, a year-on-year decrease of 11.9%; profit attributable to company owners of HK$540 million, a year-on-year decrease of 16.3%; basic profit per share of HK$0.65; and proposed to pay a final dividend of HK$0.33 per common share.
Tong Ren Tang Sinopharm will pay a final dividend of HK$0.33 per share on June 17
Tong Ren Tang Sinopharm (03613) announced that the company will pay a final dividend of HK$0.33 per share on June 17, 2024.
Tong Ren Tang Sinopharm (03613) will pay a final dividend of HK$0.33 per share on June 17
Tong Ren Tang Sinopharm (03613) announced that the company will pay a final dividend of 0 per share on June 17, 2024...
Tong Ren Tang Sinopharm (03613) announced 2023 annual results. Profit attributable to shareholders of HK$540 million decreased by 16.3% year-on-year
Tongrentang Sinopharm (03613) announced its annual results for the year ended December 31, 2023, and the group achieved acceptance during the period...
TONGRENTANGCM: (1) Annual Results Announcement For the Year Ended 31 December 2023; and (2) Inside Information - Revised Dividend Policy
Tong Ren Tang Sinopharm (03613.HK) will hold a board meeting on March 14 to approve the annual results
Gelonghui, March 4, 丨 Tong Ren Tang Sinopharm (03613.HK) announced that the company's board of directors meeting will be held on March 14, 2024 (Thursday) to approve (among other things) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider paying a final dividend (if any).
TONGRENTANGCM: Date of Board Meeting
Tong Ren Tang Sinopharm (03613) fell 4.90% and now reports 8.750 yuan, a 52-week low
As of 16:08, Tongrentang Sinopharm (03613) is down 4.90% from yesterday's closing price and now reports a 52-week low of $8.750; the trading volume is 5.202,900 shares, with a turnover of HK$46.48,800.
Changes in Hong Kong stocks | Tong Ren Tang Sinopharm (03613) is now down more than 5%. Annual revenue and profit are expected to decline year-on-year, and the agency says Ganoderma lucidum spore powder is in a period of adjustment
Tong Ren Tang Sinopharm (03613) is now down more than 5%. As of press release, it is down 5.5% to HK$9.1, with a turnover of HK$11.493,900.
Damo: Lowering the target price of Tong Ren Tang Sinopharm (03613) by 7% to HK$17 rating “increase”
Damo lowered the profit forecast for Tongrentang Sinopharm (03613) for 2024-30 by 8%-13%.
Changes in Hong Kong stocks | Tong Ren Tang Sinopharm (03613) falls more than 10%, and its annual revenue is expected to drop 11%-15% year on year
Tong Ren Tang Sinopharm (03613) fell by more than 10%, down 10.16% at press time, to HK$9.99, with a turnover of HK$499,500.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Tong Ren Tang Sinopharm (03613) Fa Ying Guang expects annual revenue to drop 11%-15% year on year
Tong Ren Tang Sinopharm (03613) announced that the year ended December 31, 2023 is expected to be compared to 2022...
TONGRENTANGCM: Inside Information - Profit Warning
Ministry of Finance: The total profit of state-owned enterprises in 2023 was 4633.28 billion yuan, up 7.4% year-on-year
From January to December, the main efficiency indicators of state-owned and state-owned enterprises across the country continued to grow steadily, and the upward trend was further consolidated.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Analysis
Price Target
No Data
